Loading clinical trials...
Loading clinical trials...
A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Efficacy of GABITRIL Treatment (up to 16 mg/Day) in Adults With Generalized Anxiety Disorder.
A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults with Generalized Anxiety Disorder.
Age
18 - 64 years
Sex
ALL
Healthy Volunteers
No
Birmingham Research Group
Birmingham, Alabama, United States
Pivotal Research Center
Mesa, Arizona, United States
Pivotal Research
Peoria, Arizona, United States
Southwestern Research
Beverly Hills, California, United States
Valley Clinical Research
El Centro, California, United States
Irvine Center for Clinical Res
Irvine, California, United States
Pharmacology Research Institute
Los Alamitos, California, United States
Pacific Institue for Medical
Los Angeles, California, United States
Pharmacology Research Institute
Newport Beach, California, United States
Pacific Clinical Research Medi
Orange, California, United States
Start Date
January 1, 2005
Completion Date
December 1, 2006
Last Updated
May 9, 2014
Gabitril
DRUG
Lead Sponsor
Cephalon
NCT07432945
NCT06661460
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07235852